Deal Details

Maravai Completes $1 Billion Follow-On Offering

Healthcare

Maravai follow-on offering

Summary

Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a portfolio company of GTCR, LLC (“GTCR”), recently completed a secondary offering of 20,000,000 shares of its Class A common stock at $50.00 per share, generating gross proceeds of approximately $1 billion. All shares sold in the offering were offered by GTCR.

Baird served as a passive book runner on this offering.

About

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The Company’s customers include many top global biopharmaceutical companies ranked by research and development expenditures according to industry consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutions and in vitro diagnostics companies. Maravai’s products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications and biologic safety testing. Maravai LifeSciences Holdings, Inc. is headquartered in San Diego, California. Founded in 1980, GTCR is a leading growth-oriented private equity firm focused on investing in growth companies in the Healthcare, Financial Services, Technology, Media & Telecommunications and Business Services industries. The Chicago-based firm pioneered The Leaders Strategy™—finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Maravai is an example of the Leaders Strategy™, whereby GTCR is partnering with Carl Hull and Eric Tardif to build and grow a leading life sciences platform. Since its inception, GTCR has invested more than $20.0 billion in over 250 companies. GTCR, LLC is headquartered in Chicago, Illinois.

Healthcare

Maravai follow-on offering